Abstract | OBJECTIVES: MATERIAL AND METHODS: RESULTS: : The mean+/-S.D. serum levels of HGFA in untreated prostate cancer and BPH cases were 0.42+/-0.24 and 0.50+/-0.26 ng/ml, respectively (no significant difference). Serum HGFA was significantly elevated in hormone-refractory prostate cancer (stage D3) compared to other stages, while HGF did not significantly differ with regard to clinical stage. CONCLUSIONS: Serum HGFA tends was elevated in patients with advanced stage prostate cancer. Further studies in large groups of patients are needed to clarify the clinical value of HGFA.
|
Authors | Osamu Nagakawa, Toshiya Yamagishi, Yasuyoshi Fujiuchi, Akira Junicho, Takuya Akashi, Kazuhiro Nagaike, Hideki Fuse |
Journal | European urology
(Eur Urol)
Vol. 48
Issue 4
Pg. 686-90
(Oct 2005)
ISSN: 0302-2838 [Print] Switzerland |
PMID | 16005141
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Hepatocyte Growth Factor
- HGF activator
- Serine Endopeptidases
|
Topics |
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
(blood)
- Case-Control Studies
- Enzyme-Linked Immunosorbent Assay
- Hepatocyte Growth Factor
(metabolism)
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Prostatic Hyperplasia
(blood, pathology)
- Prostatic Neoplasms
(blood, pathology)
- Serine Endopeptidases
(blood)
|